CareLit Fachartikel
Cost-effectiveness of M. tuberculosis specific Interferon-gamma release assay testing for the treatment of latent tuberculosis infection in Switzerland
R Diel, P Wrighton-Smith, J Zellweger · Pneumologie · 2007 · Heft 03
Dokument
1105957
CareLit-ID
Jahr
2007
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Objectives: To assess the cost-effectiveness of the new T-SPOT®.TB assay versus the Tuberculin Skin Test (TST) for screening contacts for latent tuberculosis (LTBI) in Switzerland. Methods: Health and economic outcomes of isoniazid (INH) treatment of 20- and 40-year-old close contacts were compared in a Markov model over a 20-year period following screening with TST only (at three cut-off values), T-SPOT.TB alone or in combination with the TST. Results: T-SPOT.TB based treatment was cost-effective at €11,621 per life-year-gained (LYG) in the younger and €23,691/LYG in the higher age group. No TST-based programs…
Schlagworte
T-Spot
Contacts
Treatment
Tuberculosis
Screening
Alone
Combination
Cost-Effective
Younger
Cost-Effectiveness
Close
Compared
Pneumologie
